Edgewise Therapeutics, Inc.
NASDAQ:EWTX
35.51 (USD) • At close October 17, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Edgewise Therapeutics, Inc. |
Symbool | EWTX |
Munteenheid | USD |
Prijs | 35.51 |
Beurswaarde | 3,329,854,373 |
Dividendpercentage | 0% |
52-weken bereik | 5.12 - 36.66 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Kevin Koch Ph.D. |
Website | https://www.edgewisetx.com |
An error occurred while fetching data.
Over Edgewise Therapeutics, Inc.
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. It develops
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)